| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008 | 983 | 2008 |
| CYP4F2 genetic variant alters required warfarin dose MD Caldwell, T Awad, JA Johnson, BF Gage, M Falkowski, P Gardina, ... Blood, The Journal of the American Society of Hematology 111 (8), 4106-4112, 2008 | 661 | 2008 |
| A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose GM Cooper, JA Johnson, TY Langaee, H Feng, IB Stanaway, UI Schwarz, ... Blood, The Journal of the American Society of Hematology 112 (4), 1022-1027, 2008 | 529 | 2008 |
| Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements CL Aquilante, TY Langaee, LM Lopez, HN Yarandi, JS Tromberg, ... Clinical Pharmacology & Therapeutics 79 (4), 291-302, 2006 | 372 | 2006 |
| Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci R Saxena, CC Elbers, Y Guo, I Peter, TR Gaunt, JL Mega, MB Lanktree, ... The American Journal of Human Genetics 90 (3), 410-425, 2012 | 319 | 2012 |
| Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study MA Perera, LH Cavallari, NA Limdi, ER Gamazon, A Konkashbaev, ... The Lancet 382 (9894), 790-796, 2013 | 305 | 2013 |
| Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci FW Asselbergs, Y Guo, EPA Van Iperen, S Sivapalaratnam, V Tragante, ... The American Journal of Human Genetics 91 (5), 823-838, 2012 | 297 | 2012 |
| Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis HJ Zhu, KS Patrick, HJ Yuan, JS Wang, JL Donovan, CL DeVane, ... The American Journal of Human Genetics 82 (6), 1241-1248, 2008 | 256 | 2008 |
| Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors EM Dunbar, BS Coats, AL Shroads, T Langaee, A Lew, JR Forder, ... Investigational new drugs 32, 452-464, 2014 | 253 | 2014 |
| Genetic and clinical predictors of warfarin dose requirements in African Americans LH Cavallari, TY Langaee, KM Momary, NL Shapiro, EA Nutescu, ... Clinical Pharmacology & Therapeutics 87 (4), 459-464, 2010 | 239 | 2010 |
| Clinical pharmacogenetics implementation: approaches, successes, and challenges KW Weitzel, AR Elsey, TY Langaee, B Burkley, DR Nessl, AO Obeng, ... American Journal of Medical Genetics Part C: Seminars in Medical Genetics …, 2014 | 192 | 2014 |
| Role of dichloroacetate in the treatment of genetic mitochondrial diseases PW Stacpoole, TL Kurtz, Z Han, T Langaee Advanced drug delivery reviews 60 (13-14), 1478-1487, 2008 | 191 | 2008 |
| Loci influencing blood pressure identified using a cardiovascular gene-centric array SK Ganesh, V Tragante, W Guo, Y Guo, MB Lanktree, EN Smith, ... Human molecular genetics 22 (8), 1663-1678, 2013 | 163 | 2013 |
| Genetic variation analyses by Pyrosequencing T Langaee, M Ronaghi Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 573 (1 …, 2005 | 163 | 2005 |
| The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects MW Hruska, JA Amico, TY Langaee, RE Ferrell, SM Fitzgerald, RF Frye British journal of clinical pharmacology 59 (1), 70-79, 2005 | 159 | 2005 |
| Inactivation of the ampD Gene inPseudomonas aeruginosa Leads to Moderate-Basal-Level and Hyperinducible AmpC β-Lactamase Expression TY Langaee, L Gagnon, A Huletsky Antimicrobial agents and chemotherapy 44 (3), 583-589, 2000 | 140 | 2000 |
| Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw J Katz, Y Gong, D Salmasinia, W Hou, B Burkley, P Ferreira, O Casanova, ... International journal of oral and maxillofacial surgery 40 (6), 605-611, 2011 | 139 | 2011 |
| CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial DM Smith, KW Weitzel, AR Elsey, T Langaee, Y Gong, DT Wake, ... Genetics in Medicine 21 (8), 1842-1850, 2019 | 135 | 2019 |
| Long-term safety of dichloroacetate in congenital lactic acidosis M Abdelmalak, A Lew, R Ramezani, AL Shroads, BS Coats, T Langaee, ... Molecular genetics and metabolism 109 (2), 139-143, 2013 | 130 | 2013 |
| Association between CARD15/NOD2 gene polymorphisms and paratuberculosis infection in cattle PJ Pinedo, CD Buergelt, GA Donovan, P Melendez, L Morel, R Wu, ... Veterinary Microbiology 134 (3-4), 346-352, 2009 | 130 | 2009 |
